SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sùrensen, P. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sùrensen, P. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Biological markers in body fluids for activity and progression in multiple sclerosis

Per Soelberg Sùrensen

MS Research Unit, The NeuroScience Centre, Copenhagen University Hospital, Rigshospitalet, DK-2100 Copenhagen, Denmark

Reliable biological markers in body fluids for disease activity and progression are important for our understanding of the pathophysiology and therapeutic decisions in various subtypes of multiple sclerosis. Sampling from body fluids such as cerebrospinal fluid, blood, and urine constitutes the problem that the local immuno-inflammatory process takes place in the central nervous system whereas the disease activity is only to some extent reflected in the systemic immune compartment. Promising results have been obtained in studies of adhesion molecules, pro-inflammatory cytokines, co-stimulatory molecules and neopterin as markers of disease activity in relapsing-remitting multiple sclerosis. However, these results apply to groups of patients but not necessarily to individual patients. Currently no single body fluid marker is sufficiently correlated to disease activity to be used in the individual patient in monitoring disease activity, progression, or therapeutic effects.

Key Words: multiple sclerosis • biological markers • surrogate markers • disease activity • CSF (cerebrospinal fluid) • blood • urine

Multiple Sclerosis, Vol. 5, No. 4, 287-290 (1999)
DOI: 10.1177/135245859900500416
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
C Malcus-Vocanson, P Giraud, F Micoud, V Janin, M H Charles, E Broussolle, G Chazot, B Mandrand, and H Perron
Glial toxicity in urine and multiple sclerosis
Multiple Sclerosis, December 1, 2001; 7(6): 383 - 388.
[Abstract] [PDF]

Home page
 Mult SclerHome page
S Skurkovich, A Boiko, I Beliaeva, A Buglak, T Alekseeva, N Smirnova, O Kulakova, V Tchechonin, O Gurova, T Deomina, et al.
Randomized study of antibodies to IFN-g and TNF-a in secondary progressive multiple sclerosis
Multiple Sclerosis, October 1, 2001; 7(5): 277 - 284.
[Abstract] [PDF]

Home page
 Eval Health ProfHome page
L. A. Jason, R. R. Taylor, C. L. Kennedy, K. Jordan, S. Song, D. E. Johnson, and S. R. Torres
Chronic Fatigue Syndrome: Sociodemographic Subtypes in A Community-Based Sample
Eval Health Prof, September 1, 2000; 23(3): 243 - 263.
[Abstract] [PDF]


Advertisement